[go: up one dir, main page]

WO2006109196A3 - Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics - Google Patents

Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics Download PDF

Info

Publication number
WO2006109196A3
WO2006109196A3 PCT/IB2006/001668 IB2006001668W WO2006109196A3 WO 2006109196 A3 WO2006109196 A3 WO 2006109196A3 IB 2006001668 W IB2006001668 W IB 2006001668W WO 2006109196 A3 WO2006109196 A3 WO 2006109196A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
compositions
hepatitis
virus
identification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/001668
Other languages
French (fr)
Other versions
WO2006109196A2 (en
Inventor
Matti Sallberg
Lars Frelin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tripep AB
Original Assignee
Tripep AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2005/003736 external-priority patent/WO2006021896A2/en
Application filed by Tripep AB filed Critical Tripep AB
Publication of WO2006109196A2 publication Critical patent/WO2006109196A2/en
Publication of WO2006109196A3 publication Critical patent/WO2006109196A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Disclosed herein is the discovery of novel NS3/4A compositions with enhanced expression abilities. Embodiments of the invention include codon optimized NS3/4A compositions and compositions with the Semliki forest virus replicon. Additional embodiments include transgenic organisms containing these NS3/4A compositions, methods of using these transgenic mice to screen and refine drugs, and the drugs refined by these methods. Additional embodiments include protease activity dependent molecules that can indicate the presence or absence of a protease inhibitor.
PCT/IB2006/001668 2005-02-04 2006-02-03 Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics Ceased WO2006109196A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US64997505P 2005-02-04 2005-02-04
US60/649,975 2005-02-04
IBPCT/IB2005/003736 2005-08-26
PCT/IB2005/003736 WO2006021896A2 (en) 2004-08-27 2005-08-26 Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
US74036205P 2005-11-28 2005-11-28
US60/740,362 2005-11-28

Publications (2)

Publication Number Publication Date
WO2006109196A2 WO2006109196A2 (en) 2006-10-19
WO2006109196A3 true WO2006109196A3 (en) 2007-03-15

Family

ID=37025261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001668 Ceased WO2006109196A2 (en) 2005-02-04 2006-02-03 Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics

Country Status (1)

Country Link
WO (1) WO2006109196A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150899A1 (en) * 2007-05-29 2008-12-11 Emory University Combination therapies for treatment of cancer and inflammatory diseases
IN2012MN02896A (en) 2010-06-24 2015-06-12 Panmed Ltd
US9321847B2 (en) 2010-09-20 2016-04-26 Ramot At Tel Aviv University Ltd. Activatable toxin complexes comprising a cleavable inhibitory peptide
US8912141B2 (en) 2011-06-23 2014-12-16 Panmed Ltd. Treatment of hepatitis C virus
RU2012112128A (en) * 2012-03-29 2013-10-10 Холин Максим Николаевич PI3K / AKT / IKK / NF-kB SIGNAL PATH INHIBITORS, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND THEIR COMPOSITIONS FOR PREVENTION AND TREATMENT OF VIRAL DISEASES
CN117085007B (en) * 2023-09-28 2024-12-20 南通大学 Application of Rubescensine A in the preparation of drugs for preventing or treating male oligoasthenospermia

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038888A2 (en) * 1998-02-02 1999-08-05 Istituto Di Ricerche Di Biologia Molecolare Peptide inhibitors of the serine protease activity associated to the ns3 protein of hcv, relevant uses and process of production
WO1999061039A2 (en) * 1998-05-22 1999-12-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel composition for modulating ischemic cell death
WO2001035959A1 (en) * 1999-11-18 2001-05-25 Astrazeneca Ab Use of thiazole derivatives for treatment/prevention of p38 kinase mediated disorders
JP2004000179A (en) * 2002-03-29 2004-01-08 Toray Ind Inc Model animal presenting chronic hepatitis C, cirrhosis and liver cancer pathology and method for producing the same
US20040229936A1 (en) * 2003-04-02 2004-11-18 Hsing-Pang Hsieh Treatment of hepatitis C virus infection with sesquiterpene lactones

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038888A2 (en) * 1998-02-02 1999-08-05 Istituto Di Ricerche Di Biologia Molecolare Peptide inhibitors of the serine protease activity associated to the ns3 protein of hcv, relevant uses and process of production
WO1999061039A2 (en) * 1998-05-22 1999-12-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel composition for modulating ischemic cell death
WO2001035959A1 (en) * 1999-11-18 2001-05-25 Astrazeneca Ab Use of thiazole derivatives for treatment/prevention of p38 kinase mediated disorders
JP2004000179A (en) * 2002-03-29 2004-01-08 Toray Ind Inc Model animal presenting chronic hepatitis C, cirrhosis and liver cancer pathology and method for producing the same
US20040229936A1 (en) * 2003-04-02 2004-11-18 Hsing-Pang Hsieh Treatment of hepatitis C virus infection with sesquiterpene lactones

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRELIN L ET AL: "Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 11, no. 6, 2004, pages 522 - 533, XP002285893, ISSN: 0969-7128 *
LERAT HERVE ET AL: "Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus", GASTROENTEROLOGY, vol. 122, no. 2, February 2002 (2002-02-01), pages 352 - 365, XP002372198, ISSN: 0016-5085 *
MAJUMDER M ET AL: "Expression of hepatitis C virus non-structural 5A protein in the liver of transgenic mice", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 555, no. 3, 18 December 2003 (2003-12-18), pages 528 - 532, XP004481044, ISSN: 0014-5793 *
PATENT ABSTRACTS OF JAPAN vol. 2003, no. 12 5 December 2003 (2003-12-05) *

Also Published As

Publication number Publication date
WO2006109196A2 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
Venkatraman Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections
Brecher et al. The flavivirus protease as a target for drug discovery
Hoenen et al. West Nile virus-induced cytoplasmic membrane structures provide partial protection against the interferon-induced antiviral MxA protein
NZ593808A (en) Inhibitors of hcv ns5a
TW200716154A (en) Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
DE602005015834D1 (en) 3,4- (CYCLOPENTYL) CONDENSED PROLIN LINES AS INHIBITORS OF THE NS3 SERINE PROTEASE OF HEPATITIS C VIRUS
PT1268519E (en) PROTEASE SERINE INHIBITORS, PARTICULARLY PROTEASE NS3 HEPATITIS C VIRUS
WO2006021896A3 (en) Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
Oliveira et al. NS3 and NS5 proteins: important targets for anti-dengue drug design
MY145081A (en) Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
EA201000556A1 (en) SPYROPYRROLIDINES AND THEIR APPLICATION TO FIGHT AGAINST INFECTING THROUGH HCV (HEPATITIS C VIRUS) AND HIV (HUMAN IMMUNODEFICIENUS VIRUS)
MY151062A (en) Pseudoinfectious flavivirus and uses thereof
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007140254A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
EP1924593B8 (en) Hcv ns3 protease inhibitors
GEP20104956B (en) Compounds for inhibiting hepatitis c viral replication and use thereof
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
CR10776A (en) HCV PROTEASA NS3 INHIBITORS
WO2006119061A3 (en) Hcv ns3 protease inhibitors
ATE434621T1 (en) NEW COMPOUNDS AS INHIBITORS OF THE NS3 SERINE PROTEASE OF THE HEPATITIS C VIRUS
WO2006130627A3 (en) Methods for treating hepatitis c
NO20064355L (en) Novel ketoamides with cyclic P4s as inhibitors of hepatitis C virus NS3 serine protease
DE602005015452D1 (en) SUBSTITUTED PROLINE AS INHIBITOR OF NS3 SERINE PROTEASE OF HEPATITE C VIRUS
MX2009011064A (en) Sulfur compounds as inhiibitors of hepatitis c virus ns3 serine protease.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06765563

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06765563

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6765563

Country of ref document: EP